Carnival Corp. (CCL) Announces $1B Common Stock Offering

Carnival Corporation & plc (NYSE: CCL; NYSE: CUK), today announced that Carnival Corporation (the "Company") has commenced an underwritten public offering of $1,000,000,000 of shares of common stock of the Company. The Company intends to grant the underwriter a 30-day option to purchase up to $150,000,000 of additional shares of common stock of the Company. The Company expects to use the net proceeds from the offering for general corporate purposes, which could include addressing 2023 debt maturities.

Goldman Sachs & Co. LLC is acting as sole bookrunner and underwriter for the proposed public offering.

An effective shelf registration statement relating to these shares of common stock was filed with the U.S. Securities and Exchange Commission ("SEC") on January 26, 2021. The common stock offering is being made only by means of a prospectus supplement and an accompanying base prospectus. A preliminary prospectus supplement and accompanying base prospectus relating to the common stock offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the common stock offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing [email protected].

PJT Partners is serving as independent financial advisor to the Company and Carnival plc.

This press release does not constitute an offer to sell or a solicitation of an offer to buy shares of common stock and shall not constitute an offer, solicitation or sale in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration and qualification under the securities laws of such state or jurisdiction. This announcement contains inside information (for the purposes of applicable UK law).

You May Also Be Interested In

• RenovoRx regains Nasdaq minimum bid price compliance
• Gossamer Bio raises up to $250M in private placement for PAH drug
• reAlpha completes $8.5M InstaMortgage acquisition